< Back to latest news & events

News

New Practice at the EPO: Divisional Applications and Sequence Listings

November 2023

Safeguard measure: Excess page fees on ST.25 sequence listings included as part of a divisional application to be waived by the EPO.

Following the implementation of WIPO Sequence standard ST.26, the EPO has required that new divisional applications filed on or after 1 July 2022 require a sequence listing in the ST.26 format, even when the parent application contained an ST.25 standard compliant sequence listing. This practice has been met with concern from practitioners regarding the risk of added subject matter.

To address the concerns around the risk of adding or losing subject matter, the EPO has announced a new safeguard measure. The safeguard measure permits applicants to file the parent application’s ST.25 sequence listing in PDF format as part of the divisional application. Importantly, the ST.25 pages included as a safeguard are excluded from the page fee calculation. Alternatively, the divisional application may be filed by reference to the parent application. In doing so, applicants have the guarantee that the ST.25 sequence listing, which is part of the application, does not contain any additional subject-matter.  In any event, an ST.26 compliant sequence listing will still also need to be filed.

Page fees already paid for pages of sequence listings not complying with WIPO Standard ST.26 will not be refunded.

Full details are expected to be published in the November issue of the Official Journal.

Latest updates

Post Sale Confusion – dupes and lookalikes beware?

Last month, the UK Supreme Court issued its highly-anticipated decision in Iconix Luxembourg Holdings SARL v Dream Pairs Europe Inc and another [2025] UKSC 25. Helpful background to the dispute …

Read article

A leading case - beware sequence errors in patent claims

Samsung Bioepis UK Ltd v Alexion Pharmaceuticals Inc [2025] EWHC 1240 (Pat) – Mr Justice Meade – 20 May 2025 The UK Patents Court has held that Samsung Bioepis’ and Amgen’s …

Read article

ICELAND left out in the cold by the General Court

Earlier in the month, the EU General Court issued its decision on Iceland Foods Ltd’s appeal of a decision of the Grand Board of Appeal of EUIPO to invalidate an …

Read article

HGF recognised in Managing IP’s New “Trusted Talent” Table in Germany

We are proud to announce that HGF has been ranked in Managing IP’s newly launched Trusted Talent table in Germany, a recognition of our ongoing commitment to excellence in intellectual …

Read article

Briefing Note: UKIPO SEP Consultation

Overview and Strategic Context The UKIPO’s 2025 consultation on Standard Essential Patents (SEPs), announced on 15 July 2025, signals a potential policy shift in how the UK approaches SEP licensing …

Read article

G1/23: The Enlarged Board of Appeal shift EPO practice towards an “on-sale” bar.

Last week, the EPO’s Enlarged Board of Appeal (EBA) issued its Decision that both a product put on the market before the date of filing of a European patent application, …

Read article

Quinas Technology Wins WIPO Global Award for Innovation in ICT

Our client, Quinas Technology, has been named the winner of the WIPO Global Award 2025 in the ICT Startup category. Quinas is a spin-out from Lancaster University. We have worked …

Read article

IP Ingredients: Summer Case Law Review 2025

As the British summer swings once again between sunburn and showers, it’s a great time to take stock of what the first half of the year has delivered by way …

Read article